Gilead Sciences, Inc. (VIE:GILD)

Market Cap	132.40B
Revenue (ttm)	24.79B
Net Income (ttm)	6.91B
Shares Out	n/a
EPS (ttm)	5.47
PE Ratio	19.16
Forward PE	15.05
Dividend	2.76 (2.58%)
Ex-Dividend Date	Dec 15, 2025

Volume	n/a
Average Volume	38
Open	105.42
Previous Close	105.46
Day's Range	105.12 - 107.02
52-Week Range	82.70 - 111.52
Beta	n/a
RSI	54.87
Earnings Date	Feb 10, 2026

About Gilead Sciences

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy p...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1987
• Employees: 17,600
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: GILD

Financial Performance

In 2024, Gilead Sciences's revenue was $28.75 billion, an increase of 6.04% compared to the previous year's $27.12 billion. Earnings were $480.00 million, a decrease of -91.53%.

Financial numbers in USD